recombinant human hyaluronidase

Phase 1Protein / enzyme

HHalozyme Therapeutics

recombinant human hyaluronidase is one of 81 small molecule programs targeting Solid Tumor. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Solid TumorRecruiting

ImmunogenicityNot yet recruiting

Solid TumorPhase 1

Recruiting

ImmunogenicityPhase 1

Not yet recruiting

Competition

Competitive Landscape

348 competitors in Solid Tumor

#DrugCompanyPhaseTrials

DATROWAY

Daiichi Sankyo

Preclinical

1 2

Sporanox

SSebela Pharmaceuticals Development LLC

Preclinical

2 3

Zejula

GGlaxo Dba Glaxosmithkline

Preclinical

2 4

Augtyro

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Preclinical

2 5

Paxil

SSebela Pharmaceuticals Development LLC

Preclinical

1 6

Epivir

GGlaxo Dba Glaxosmithkline

Preclinical

1 7

Navmi

SSummit Therapeutics

Preclinical

1 8

PD-1 Inhibitor

Johnson & Johnson

Preclinical

1 9

Chemotherapy Drug

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Preclinical

2 10

SAR445877

Sanofi

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1Not yet recruiting

Immunogenicity

NCT07484893

Q3 2029

Phase 1Recruiting

Solid Tumor

NCT07161414

Clinical

Trials by Indication[1]

Type 1 Diabetes Mellitus4 trials

Safety Study of Subcutaneously-Injected Prandial INSULIN-PH20 NP Compared to Insulin Lispro Injection in Participants With Type 1 Diabetes Mellitus

Completed·HHalozyme Therapeutics·Phase 2·NCT00883558·48 enrolled

Safety/Efficacy Study of Subcutaneously Injected Prandial Insulins Compared to Insulin Lispro Alone in Participants With Type 1 Diabetes Mellitus

Completed·HHalozyme Therapeutics·Phase 2·NCT01194245·135 enrolled

Phase II Pharmacokinetics Study of Humalog and Humulin-R With and Without rHuPH20 in Type 1 Diabetes Mellitus

Completed·HHalozyme Therapeutics·Phase 2·NCT00774800·22 enrolled

Show 1 more trial

Randomized, Double-blind, Crossover, Pharmacokinetic (PK) and Glucodynamic (GD) Study of Continuous Subcutaneous Insulin Infusion (CSII) in Participants With Type 1 Diabetes Mellitus (T1DM)

Completed·HHalozyme Therapeutics·Phase 1·NCT01275131·45 enrolled

Type 2 Diabetes Mellitus2 trials

Liquid Meal Study With Insulin Lispro With/Without Recombinant Human Hyaluronidase PH20 (rHuPH20) and Regular Human Insulin With rHuPH20 to Compare Pharmacokinetics, Postprandial Glycemic Response, and Optimal Insulin Dose in Participants With Type 2 Diabetes Mellitus (T2DM)

Completed·HHalozyme Therapeutics·Phase 2·NCT00916357·23 enrolled

Safety/Efficacy Study of Subcutaneously Injected Prandial Insulins Compared to Insulin Lispro Alone in Patients With Type 2 Diabetes Mellitus

Completed·HHalozyme Therapeutics·Phase 2·NCT01194258·132 enrolled

Immunogenicity1 trial

A Study to Evaluate the Safety, PK, and Immunogenicity of Recombinant Human Hyaluronidase in Healthy Subjects

Not yet recruiting· Shanghai Henlius Biotech logo

Shanghai Henlius Biotech·Phase 1·NCT07484893·24 enrolled

Lymphedema1 trial

Recombinant Human Hyaluronidase in Treating Lymphedema in Patients With Cancer

Terminated·SStanford University·Phase 1/2·NCT01928030·3 enrolled

Randomized1 trial

Randomized, Double Blind, 2 Way Crossover Study of CSII With, Versus Without, Pretreatment With Human Hyaluronidase

Completed·HHalozyme Therapeutics·Phase 4·NCT01526733·25 enrolled

5 more indications

MPA1 trial

A Pharmacokinetic and Glucodynamic Study of Subcutaneously Administered Insulin Analogs With rHuPH20 Compared to Insulin Analogs Alone

Completed·HHalozyme Therapeutics·Phase 1·NCT00979875·14 enrolled

Adult1 trial

Study to Evaluate Pharmacokinetic (PK), Safety and Tolerability of Cabotegravir (CAB) 400 Milligrams Per Milliliter (mg/mL) Formulation in Healthy Adult Participants

Completed· GSK logo

GSK·Phase 1·NCT04484337·138 enrolled

Intravenous1 trial

Subcutaneous Rehydration Compared to Intravenous Rehydration

Completed·HHalozyme Therapeutics·Phase 4·NCT00773175·148 enrolled

Solid Tumor1 trial

A Phase I, Multicenter, Dose Finding and Dose Confirmation Study to Investigate the Pharmacokinetics, and Safety of Subcutaneous Rilvegostomig in Adult Participants With Advanced Solid Tumors Previously Treated With Standard of Care Therapy (ARTEMIDE-subQ)

Recruiting· AstraZeneca logo

AstraZeneca·Phase 1·NCT07161414·40 enrolled

Unspecified3 trials

Study of Subcutaneous Hydration Enabled by Human Recombinant Hyaluronidase (Hylenex)

Completed·HHalozyme Therapeutics·Phase 4·NCT00656370·15 enrolled

Tolerability and Safety of IGI, 10% With rHuPH20 in PIDD

Completed·BBaxalta now part of Shire·Phase 2/3·NCT01485796·54 enrolled

Pharmacokinetic (PK), Pharmacodynamic (PD), and Safety Study of Subcutaneously Administered Humalog® With and Without Recombinant Human Hyaluronidase (rHuPH20)and Humulin-R® With and Without rHuPH20

Completed·HHalozyme Therapeutics·Phase 1·NCT00705536·26 enrolled

Sources

References

[1]
ClinicalTrials.gov — 16 trial records for recombinant human hyaluronidase. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — recombinant human hyaluronidase compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for recombinant human hyaluronidase. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Halozyme Therapeutics company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Protein / enzyme[2]
Highest Phase: Phase 1[1]
Company: HHalozyme Therapeutics

recombinant human hyaluronidase

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q3 2029

Trials by Indication[1]

Type 1 Diabetes Mellitus4 trials

Type 2 Diabetes Mellitus2 trials

Immunogenicity1 trial

Lymphedema1 trial

Randomized1 trial

MPA1 trial

Adult1 trial

Intravenous1 trial

Solid Tumor1 trial

Unspecified3 trials

References

Drug Info

Quick Facts

Related News